Stanford geneticist uses Co-Scientist to help find new treatments for chronic liver disease and liver fibrosis.
arXiv:2607. 02944v1 Announce Type: cross Abstract: We propose PRECEDE, a precedent-guided co-scientist for side-effect-aware drug redesign that revises a parent compound to mitigate a specified side effect while preserving therapeutic function.
By Yujin Kim, Charmgil Hong
arXiv:2502. 18864v2 Announce Type: replace Abstract: Scientific discovery is driven by scientists generating novel hypotheses for complex problems that undergo rigorous experimental validation.
By Juraj Gottweis, Wei-Hung Weng, Alexander Daryin, Tao Tu, Petar Sirkovic, Artiom Myaskovsky, Grzegorz Glowaty, Felix Weissenberger, Alessio Orlandi, Dan Popovici, Anil Palepu, Keran Rong, Ryutaro Tanno, Khaled Saab, Fan Zhang, Jacob Blum, Andrew Carroll, Kavita Kulkarni, Nenad Tomasev, Dina Zverinski, Ivor Rendulic, Elahe Vedadi, Florian Hasler, Luka Rimanic, Marina Boia, Ivan Budiselic, Ben Feinstein, Mathias Bellaiche, Tom Sheffer, Jan Freyberg, Jeremy Ratcliff, Ottavia Bertolli, Katherine Chou, Avinatan Hassidim, Burak Gokturk, Amin Vahdat, Yuan Guan, Vikram Dhillon, Eeshit Dhaval Vaishnav, Byron Lee, Tiago R D Costa, Jos\'e R Penad\'es, Gary Peltz, Yossi Matias, James Manyika, Demis Hassabis, Yunhan Xu, Pushmeet Kohli, Annalisa Pawlosky, Alan Karthikesalingam, Vivek Natarajan
Clare Bryant uses Co-Scientist to identify genetic triggers in emerging infectious diseases.
arXiv:2607. 11084v1 Announce Type: new Abstract: Agentic research systems are emerging as a new paradigm for coordinating scientific workflows beyond isolated model inference, code generation, or statistical analysis.
By Eddie Huang (NVIDIA AI Technology Center, NVIDIA Corporation), Ken Liao (NVIDIA AI Technology Center, NVIDIA Corporation), Iven Fu (NVIDIA AI Technology Center, NVIDIA Corporation), Yang-Hsien Lin (NVIDIA AI Technology Center, NVIDIA Corporation), Chao-Shun Zhan (NVIDIA AI Technology Center, NVIDIA Corporation), Andy Liao (NVIDIA AI Technology Center, NVIDIA Corporation), Virginia Chen (NVIDIA AI Technology Center, NVIDIA Corporation), Johnson Sun (NVIDIA AI Technology Center, NVIDIA Corporation), Pika Wang (NVIDIA AI Technology Center, NVIDIA Corporation), Richard Huang (NVIDIA AI Technology Center, NVIDIA Corporation), Jiun-Cheng Jiang (NVIDIA AI Technology Center, NVIDIA Corporation), Ting-Yuan Liu (Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, Master Program for Digital Health Innovation, China Medical University, Taichung, Taiwan), Hsing-Fang Lu (Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan), Ray Y. Lee (AI-Driven Genomic Medicine and Drug Discovery Lab, China Medical University Hospital, Taichung, Taiwan), Chi-Chou Liao (Department of Medical Research, China Medical University Hospital, Taichung, Taiwan), Simon See (NVIDIA AI Technology Center, NVIDIA Corporation), Fuu-Jen Tsai (Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan)
OpenAI introduces GPT-Rosalind, a frontier reasoning model built to accelerate drug discovery, genomics analysis, protein reasoning, and scientific research workflows.